Search results
Results from the WOW.Com Content Network
Dopamine receptors are a class of G protein-coupled receptors that are prominent in the vertebrate central nervous system (CNS) and are implicated in many neurological processes, including motivational and incentive salience, cognition, memory, learning, and fine motor control, as well as modulation of neuroendocrine signaling.
Numerous clinical trials have been performed to assess the use of dopamine agonists for the treatment of restless legs syndrome (RLS). RLS is identified by the strong urge to move and is a dopamine-dependent disorder. RLS symptoms decrease with the use of drugs that stimulate dopamine receptors and increase dopamine levels, such as dopamine ...
The drug was intended as a prodrug but may also directly interact with the dopamine D 1-like and/or D 2-like receptors. [ 1 ] [ 5 ] [ 4 ] [ 6 ] DA-Phen has shown centrally mediated effects in animals, including increased cognitive flexibility , improved spatial learning and memory , antidepressant - and anxiolytic -like effects, and decreased ...
Dopamine receptor agonists can be divided into non-selective dopamine receptor agonists, D 1-like receptor agonists, and D 2-like receptor agonists. Non-selective dopamine receptor agonists include dopamine, deoxyepinephrine (epinine), dinoxyline, and dopexamine. They are mostly peripherally selective drugs, are often also adrenergic receptor ...
The primary endogenous agonists of the sympathetic nervous system are the catecholamines (i.e., epinephrine [adrenaline], norepinephrine [noradrenaline], and dopamine), which function as both neurotransmitters and hormones. Sympathomimetic drugs are used to treat cardiac arrest and low blood pressure, or even delay premature labor, among other ...
The drug is a centrally permeable monoamine precursor and prodrug of dopamine and hence acts as a dopamine receptor agonist. [3] Chemically, levodopa is an amino acid, a phenethylamine, and a catecholamine. [3] Levodopa was first synthesized and isolated in the early 1910s. [3] The antiparkinsonian effects of levodopa were discovered in the ...
These drugs show greater magnitudes of impact on dopamine levels than do dopamine reuptake inhibitors like methylphenidate. [ 62 ] [ 63 ] In addition, whereas dopamine reuptake inhibitors show a clear dose–effect ceiling in their effects on dopamine levels, dopamine releasing agents do not and have been found to maximally increase dopamine ...
By acting as an agonist for the D 2, D 3, and D 4 dopamine receptors, Pramipexole may directly stimulate the underfunctioning dopamine receptors in the striatum, thereby restoring the dopamine signals needed for proper functioning of the basal ganglia. Pramipexole can increase growth hormone indirectly through its inhibition of somatostatin. [37]